Cite

    Garbarino, V. et al. (n.d.). A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes. Alzheimer's & dementia. p. n/a. [Online].